Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sangamo BioSciences, CIRM In Strategic Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Sangamo BioSciences, CIRM In Strategic Pact

To develop ZFP therapeutic for blood disease

Sangamo BioSciences has received a $6.4 million Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to use its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic stem cells (HSCs) to develop a potential ZFP Therapeutic for beta-thalassemia.
 
The four-year grant provides matching funds for preclinical work to support an IND application and a Phase I trial in transfusion-dependent beta-thalassemia, a genetic blood disease caused by mutations in the beta-globin gene.
 
“CIRM support for this program is yet another major validation of our ZFP Therapeutics platform,” said Edward Lanphier, Sangamo’s president and chief executive officer. “The award will assist the development of our stem cell-based ZFP Therapeutic for the potential cure of thalassemia. Importantly, this same approach can be directly applied to related hemoglobinopathies such as sickle cell disease. We look forward to working with a team of world-renowned experts in this field, including the team at Children’s Hospital & Research Center Oakland and our colleagues at CIRM, to bring this treatment through IND application and into a Phase I trial.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters